左乙拉西坦口服液致肝损伤1例分析

doi:10.19803/j.1672-8629.2020.12.21

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (12): 943-945.
DOI: 10.19803/j.1672-8629.2020.12.21

左乙拉西坦口服液致肝损伤1例分析

杨贝¹, 方玉婷^2*

¹银川市第一人民医院药学部,宁夏银川 750001;
²中国科学技术大学附属第一医院(安徽省立医院)药剂科,安徽合肥 230031

收稿日期:2019-10-21 修回日期:2020-12-07 出版日期:2020-12-15 发布日期:2020-12-07
通讯作者: ^*方玉婷,女,硕士研究生,医院药学、临床药学。E-mail:29144389@qq.com
作者简介:杨贝,女,硕士研究生,小儿用药临床药师。

Analysis of One Case of Liver Injury Induced by Levetiracetam Oral Liquid

YANG Bei¹, FANG Yuting^2*

¹Department of Pharmacy,the first people's Hospital of Yinchuan,Yinchuan Ningxia 750001,China;
²Department of Pharmacy,the First Affiliated Hospital of USTC,Hefei Anhui 230031,China

Received:2019-10-21 Revised:2020-12-07 Online:2020-12-15 Published:2020-12-07

摘要/Abstract

摘要： 目的提醒临床医生在使用左乙拉西坦时需密切关注用药安全。方法报道1例癫痫患儿使用左乙拉西坦后出现肝功能损伤的病例资料,查阅文献分析该药导致肝功能损伤的相关性和发病机制。结果该患儿停用左乙拉西坦后肝酶显著下降,通过因果关系评估表评估得分为6分,相关性判断为很可能。结论当患者使用左乙拉西坦时需考虑到该药所致肝酶升高的可能性,尤其在儿童中使用时需注意进行肝功能监测。

关键词: 左乙拉西坦, 药物性肝损伤, 抗癫痫药物, 肝毒性

Abstract: Objective To remind the medical staff to pay close attention to medication safety of levetiracetam.Methods An epileptic pediatric patient who developed a significant elevation of the liver enzymes during levetiracetam monotherapy was reported while literature about the relativity and pathogenesis of levetiracetam-induced liver injury was consulted.Results The liver enzymes were surprisingly decreased to normal after levetiracetam discontinuation in this patient. The Roussel Uclaf causality assessment method score was 6, indicating levetiracetam was a probable cause for the liver damaged.Conclusion The levetiracetam-associated potential liver enzymes elevation should be considered when levetiracetam is prescribed to patients, especially pediatric patients, close liver function monitoring was necessary..

Key words: levetiracetam, drug-induced liver injury, antiepileptic drugs, hepatotoxicity

中图分类号:

R994.11

杨贝, 方玉婷. 左乙拉西坦口服液致肝损伤1例分析[J]. 中国药物警戒, 2020, 17(12): 943-945.

YANG Bei, FANG Yuting. Analysis of One Case of Liver Injury Induced by Levetiracetam Oral Liquid[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 943-945.

参考文献

[1] Tang H P,Wang M H,Jian A,et al.Clinical trial of levetiracetam tablets in the treatment of children’s intractable Epilepsy[J].The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志),2017,33(22):2247-2249.
[2] Sun N,Huang S P,Yang L,et al.Clinical observation on levetiracetam as add-on or monotherapy of electrical status epilepticusin during sleep[J].Chinese Journal of Child Health Care(中国儿童保健杂志),2016,24(11):1183-1186
[3] Han JY,Moon CJ,Youn YA,et al.Efficacy of levetiracetam for neon-atal seizures in preterm infants[J].BMC Pediatrics,2018,18(1):131.
[4] Velayudham LS,Farrell GC.Drug-induced cholestasis[J].Expert Opinion on Drug Safety,2003(2):287-304.
[5] Drug-induced Liver Disease Study Group.Guidelines for the management of drug-induced liver injury[J].Journal of Clinical Hepatology(临床肝胆病杂志),2015,31(11):1752-1769
[6] Chen DF,Sun WJ,Xiong J.Diagnosis and treatment of drug-induced liver injury[J].Chinese Journal of Hepatology(中华肝脏病杂志),2012,20(3):170-172.
[7] Guo TT.One Case of Severe Liver Injury Induced by Cefotaxime Sodium and Sulbactam Sodium for Injection[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(3):189-190.
[8] Mao JJ.One Case of Hepatic Dysfunction Induced by Sodium Valproate for Injection[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2018,15(3):191-192.
[9] Gallerani M,Mari E,Boari B,et al.Pancytopenia associated with levetiracetam treatment[J].Clinical Drug Investigation.2009,29(11):747-51.
[10] National Institutes of Health.Clinical and Research Information on Drug-Induced Liver Injury[M/OL].United States National Library of Medicine,2013[2019-10-12] http://livertox.nih.gov/Fluconazole.htm.
[11] Azar NJ,Aune P.Acute pancreatitis and elevated liver transam-inases after rapid titration of oral levetiracetam[J].Journal of Clinical Neuroscience,2014,21(6):1053-1054.
[12] Sethi NK,Sethi PK,Torgovnick J,et al.Asymptomatic elevation of liver enzymes due to levetiracetam:a case report[J].Drug Metabolism and Drug Interactions,2013,28(2):123-124.
[13] Broli M,Provini F,Naldi I,et al.Unexpected gamma glutamyltran-sferase rise increase during levetiracetam monotherapy[J].Epileptic Disorders,2010,12(1):81-82.
[14] Xiong N,Hou L,Lu N,et al.Probable levetiracetam-related serum alkaline phosphatase elevation[J].Bmc Neurology,2012,12(1):97.
[15] Gomez-zorrilla S,Ferraz AV,Pedros C,et al.Levetiracetam-Induced Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome[J].Annals of Pharmacotherapy,2012,46(7-8):e20.

左乙拉西坦口服液致肝损伤1例分析

Analysis of One Case of Liver Injury Induced by Levetiracetam Oral Liquid

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	王欣, 史磊磊, 张雨涵, 谢允东, 刘继平. 多药耐药相关蛋白转运体在药物性肝损伤中的作用研究进展[J]. 中国药物警戒, 2024, 21(2): 229-234.
[2]	高源, 石伟, 肖小河, 柏兆方, 王伽伯. 特异质型药物性肝损伤体内评价模型研究进展[J]. 中国药物警戒, 2024, 21(1): 33-39.
[3]	尚慧莹, 魏雪, 程宏愽, 马增春, 涂博丹, 肖成荣, 刘献, 高月. 基于高内涵技术的补骨脂肝毒性成分筛选研究[J]. 中国药物警戒, 2024, 21(1): 74-82.
[4]	詹姆斯·布坎南. 用 nR 改良海氏法则及 P_ALT 评估药物性肝损伤研究进展[J]. 中国药物警戒, 2024, 21(1): 117-120.
[5]	梁栋, 罗莉, 程均祥. 左乙拉西坦不良反应分析[J]. 中国药物警戒, 2023, 20(9): 1054-1059.
[6]	张琴, 张陆勇, 江振洲. 过氧化物酶体增殖物激活受体激动剂安全性研究进展[J]. 中国药物警戒, 2023, 20(8): 950-955.
[7]	陈林珍, 王璇, 张晓朦, 马志强, 陆珊, 吴嘉瑞, 赵崇军, 张冰. 基于斑马鱼模型的杠柳毒苷肝毒性评价[J]. 中国药物警戒, 2023, 20(7): 742-748.
[8]	陈崇泽, 李婕, 旷煉, 檀学文, 刘敏惠, 刘熙, 郑燕钗, 靳洪涛. 448例住院患者药物性肝损伤相关不良反应特征分析[J]. 中国药物警戒, 2023, 20(6): 697-704.
[9]	朱春雾, 余雪君, 孙鑫, 刘成海. 仙灵骨葆胶囊肝毒性研究进展[J]. 中国药物警戒, 2023, 20(5): 496-499.
[10]	罗琼, 李盟, 李光耀, 何彦春, 周祖山, 孙鑫, 刘成海. 635例类风湿性关节炎患者应用雷公藤制剂所致肝损伤的中医证候及联合用药特点[J]. 中国药物警戒, 2023, 20(5): 500-504.
[11]	李容容, 李盟, 苟悦, 罗琼, 吕桦, 孙鑫, 刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析[J]. 中国药物警戒, 2023, 20(5): 505-510.
[12]	姚克宇, 张舒琪, 金锐, 刘丽红, 朱彦. 药物致肝损伤数据集的比较研究[J]. 中国药物警戒, 2023, 20(5): 568-573.
[13]	陈超, 朱兰, 刘丽红, 韩佳寅, 朱彦. 文献来源的补骨脂及其制剂引起药物性肝损伤特点探析[J]. 中国药物警戒, 2023, 20(4): 449-453.
[14]	王宇, 黄婧怡, 侯立新, 李爽, 崔永康, 黄兰蔚. 社区获得性肺炎患者抗生素相关性肝损伤外周血体液免疫特点分析[J]. 中国药物警戒, 2023, 20(2): 132-135.
[15]	于洁, 朱浩翔, 张继明. 疑似千里光类药物致药物性肝损伤1例分析[J]. 中国药物警戒, 2023, 20(2): 136-139.